ECM
GMAB icon

ExodusPoint Capital Management’s Genmab GMAB Stock Holding History

ExodusPoint Capital Management’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-13,015
Closed -$389K – 1686
2024
Q1 		$389K Buy
+13,015
New +$382K ﹤0.01% 1196
2022
Q2 		– Sell
-6,925
Closed -$251K – 2122
2022
Q1 		$251K Buy
+6,925
New +$238K ﹤0.01% 1825

Other funds holding GMAB

AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ExodusPoint Capital Management's GMAB Position: Q2 2024 in Review

ExodusPoint Capital Management sold out of Genmab (GMAB) in Q2 2024, closing a stake of 13,015 shares — an estimated $389K sold.

ExodusPoint Capital Management first reported a position in GMAB in Q1 2022 and held it in 2 quarters. The position peaked at $389K in Q1 2024. 219 funds tracked by Wall St. Rank hold GMAB as of Q2 2024.

  • ExodusPoint Capital Management reported no remaining Genmab position as of Q2 2024 after selling out during the quarter.
  • ExodusPoint Capital Management sold 13,015 Genmab shares in Q2 2024, an estimated $389K.
  • ExodusPoint Capital Management first reported a position in Genmab in Q1 2022 and held it in 2 quarters.
  • ExodusPoint Capital Management's Genmab position peaked at $389K in Q1 2024.
  • 219 funds tracked by Wall St. Rank held Genmab as of Q2 2024.

Based on ExodusPoint Capital Management's 13F filing for Q2 2024, filed 13 Aug 2024.